# Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR

> **NCT07129421** · NA · NOT_YET_RECRUITING · sponsor: **Emblok, Inc.** · enrollment: 560 (estimated)

## Conditions studied

- AORTIC VALVE DISEASES
- Aortic Valve Stenosis and/or Insufficiency
- Aortic Valve Regurgitation
- Aortic Valve Replacement

## Interventions

- **DEVICE:** EMBLOK™ Embolic Protection System ("EMBLOK EPS")

## Key facts

- **NCT ID:** NCT07129421
- **Lead sponsor:** Emblok, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-03-15
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07129421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07129421, "Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07129421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*